The Effect of Using Desensitizers Containing S-PRG In Treatment Of Dentin Hypersensitivity Over 6 Months: A Randomized Clinical Trial
Launched by EMAN OMAR ELFAROUK · Feb 23, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective a new type of desensitizer, which contains a substance called S-PRG, is in reducing tooth sensitivity compared to a standard treatment made with sodium fluoride. Dentin hypersensitivity can cause discomfort when you eat or drink hot, cold, or sweet things, and the goal is to see if the new treatment can help patients feel better over a six-month period. Participants will be asked to report the level of pain they experience using a simple scale.
To be eligible for this trial, participants should be adults aged 18 to 75 with good oral hygiene and healthy gums. They need to have at least 20 natural teeth and experience some sensitivity in at least two teeth. However, those with certain health issues, allergies to the study ingredients, or who have recently used desensitizing treatments will not be able to participate. If chosen for the trial, participants can expect regular check-ins to assess their pain levels and overall oral health during the six months. This study aims to find a better way to manage tooth sensitivity, which could improve many people's quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Good oral hygiene.
- • Cooperative patients who show interest to participate in the study and welling to sign the informed consent.
- • Healthy patients with no history of previous systematic diseases that can affect their oral health.
- • Normal and healthy gingival tissue.
- • Teeth that have no cavitation or restorations.
- • Patients with at least 20 natural permanent teeth and at least two teeth with a VAS score from 4 to 10.
- • Anterior teeth.
- Exclusion Criteria:
- • Allergic to the ingredients used in the study.
- • Gastrointestinal disorders (They have repeated vomiting attacks).
- • Medically compromised (They cannot tolerate the procedures).
- • Taking desensitizing treatment in the last 6 months (It affects the outcome).
- • Taking anti-inflammatory drugs (It affects the hypersensitivity perception).
- • Pregnant females (They complain from nausea and repeated vomiting attacks)
- • Smokers (Smoking will affect the oral hygiene and periodontal health).
About Eman Omar Elfarouk
Eman Omar Elfarouk is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Eman leads initiatives that bridge the gap between scientific discovery and clinical application. Her expertise encompasses a wide range of therapeutic areas, and she is adept at navigating the complexities of regulatory environments to ensure compliance and foster collaboration among stakeholders. Through strategic planning and a patient-centered approach, Eman aims to contribute to the development of safe and effective treatments, ultimately enhancing the quality of care in the healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cairo, Elmanil, Egypt
Cairo, , Egypt
Patients applied
Trial Officials
Eman Omar, bachelor
Principal Investigator
Cairo University faculty of oral and dental medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported